Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: Implications for antimicrobial stewardship programmes

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2146-2151

  Shah, D N ^a,b   Yau, R ^a,b   Weston, J ^a,b   Lasco, T M ^a,b   Salazar, M ^a,b   Palmer, H R ^a,b   Garey, K W ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Candida; Echinocandins; Fluconazole

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL THERAPY; ANTIMICROBIAL STEWARDSHIP PROGRAM; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CAUCASIAN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH PROGRAM; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY;

AGED; ANTIFUNGAL AGENTS; APACHE; CANDIDA; CANDIDEMIA; DRUG UTILIZATION; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80051693276     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr244     Document Type: Article

References (15)

1. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
2. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
3. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
4. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
5. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
6. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004; 48: 153-60.
7. Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 2006; 19: 538-43.
8. Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007; 16: 919-27.
9. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
10. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-9.
11. Hadley S, Martinez JA, McDermott L et al. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother 2002; 49: 415-9.
12. Baddley JW, Patel M, Jones M et al. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis 2004; 50: 119-24.
13. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
14. Amrutkar PP, Rege MD, Chen H et al. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection 2006; 34: 322-7.
15. Lau A, Chen S, Sleiman S et al. Current status and future perspectives on molecular and serological methods in diagnostic mycology. Future Microbiol 2009; 4: 1185-222.